Abstract
Objective To report current practices and attitudes of child and adolescent psychiatrists (CAP) regarding diagnostic genetic and pharmacogenetic (PGx) testing.
Methods Survey of 958 US-based practicing CAP.
Results 54.9% of respondents indicated that they had ordered/referred for a genetic test in the past 12 months. 87% of respondents agreed that it is their role to discuss genetic information regarding psychiatric conditions with their patients; however, 45% rated their knowledge of genetic testing practice guidelines as poor/very poor. The most ordered test was PGx (32.2%), followed by chromosomal microarray (23.0%). 73.4% reported that PGx is at least slightly useful in child and adolescent psychiatry. Most (62.8%) were asked by a patient/family to order PGx in the past 12 months and 41.7% reported they would order PGx in response to a family request. Those who ordered a PGx test were more likely to have been asked by a patient/family and to work in private practice. 13.8% of respondents agreed/strongly agreed that a PGx test can predict the effectiveness of specific antidepressants. Some respondents also indicated they would make clinical changes based on PGx information even if a medication was currently effective and there were no side effects.
Conclusions Genetic testing has become routine clinical care in child and adolescent psychiatry. Despite this, many providers rate their associated knowledge as poor/very poor. Patient requests were associated with ordering practices and providers misinterpretation of PGx may be leading to unnecessary changes in clinical management. There is need for further education and support for clinicians.
Competing Interest Statement
Dr. Soda receives grant support from NIH. Dr. Merner reports no financial relationships with commercial interests. Dr. Small receives grant support from NIH. Ms. Torgerson reports no financial relationships with commercial interests. Ms. Muñoz reports no financial relationships with commercial interests. Dr. Austin receives support from BC Mental Health and Substance Use Services, and grant funding from Genome BC/Genome Canada, and the Canadian Institutes of Health Research. They have consulted for 23andme. Dr. Storch is a consultant for Biohaven and Brainsway. He receives grant support from NIH, International OCD Foundation, and Ream Foundation. He owns stock valued under $5000 in Nview. He receives book royalties from Elsevier, Springer, Oxford, Guilford, American Psychological Association, Lawrence Erlbaum, and Jessica Kingsley. Dr. Pereira receives grant support from NIH. Dr. Lázaro-Muñoz receives grant support from NIH.
Funding Statement
This research was supported by the National Institutes of Health under Award Numbers 3R00HG008689 and R01MH128676, and P50HD103555 for the use of the Clinical and Translational Core facilities.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Baylor College of Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Disclosures Dr. Soda receives grant support from NIH.
Dr. Merner reports no financial relationships with commercial interests.
Dr. Small receives grant support from NIH.
Ms. Torgerson reports no financial relationships with commercial interests.
Ms. Muñoz reports no financial relationships with commercial interests.
Dr Austin receives support from BC Mental Health and Substance Use Services, and grant funding from Genome BC/Genome Canada, and the Canadian Institutes of Health Research. They have consulted for 23andme.
Dr. Storch is a consultant for Biohaven and Brainsway. He receives grant support from NIH, International OCD Foundation, and Ream Foundation. He owns stock valued under $5000 in Nview. He receives book royalties from Elsevier, Springer, Oxford, Guilford, American Psychological Association, Lawrence Erlbaum, and Jessica Kingsley.
Dr. Pereira receives grant support from NIH.
Dr. Lázaro-Muñoz receives grant support from NIH.
Data Availability
De-identified survey data are available on request from the corresponding author. Data will be made available to researchers whose proposed use of the data has been approved by the study team.
